Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat
Status:
Completed
Trial end date:
2019-02-26
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to investigate whether there is a clinically
meaningful effect on QTc change from baseline relative to placebo after administration of 10
mg at steady state in patients with stable CAD (coronary artery disease).
Phase:
Phase 1
Details
Lead Sponsor:
Bayer
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination